# A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases

> **NCT02633397** · PHASE2 · COMPLETED · sponsor: **Mark Gladwin** · enrollment: 130 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Riociguat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02633397
- **Lead sponsor:** Mark Gladwin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-11
- **Primary completion:** 2022-05-04
- **Final completion:** 2022-05-04
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2023-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02633397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02633397, "A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02633397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*